NBP
NovaBridge Biosciences
NASDAQ · Healthcare · Biotechnology · US
$1.80
+0.00%Year over year
Reported trailing growth
- Revenue
- —
- EBITDA
- +89.2%
- EBIT
- +85.3%
- EPS
- —
- Free cash flow
- —
- Operating cash flow
- —
Forward estimates
Based on analyst estimates
- Revenue
- —
- EBITDA
- —
- EPS
- -82.1%
Three-year CAGR
- Revenue
- —
- EBITDA
- +96.4%
- EBIT
- +96.4%
- Net income
- +95.9%
- EPS
- +96.4%
- Free cash flow
- +94.6%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Dec 1, 2025